Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 3Recruiting 2Withdrawn 1Terminated 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 19Myeloid 8Sarcoma 1Lymphoid 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1CNS 1Breast 1

Conditions

Sarcoma 1Neoplasms, Germ Cell and Embryonal 1Melanoma 1Carcinoma, Renal Cell 1

Interventions

Cyclophosphamide 9Radiotherapy 8Temozolomide 6Magnetic Resonance Spectroscopy 6Filgrastim 6Doxorubicin 6pazopanib 5Gemcitabine 5pembrolizumab 4Vincristine 4Radiation 4Etoposide 4Docetaxel 4Carboplatin 4Biopsy 4Trabectedin 3Taxes 3Specimen Handling 3Paclitaxel 3Nivolumab 3Irinotecan 3Drug Therapy 3olaparib 2niraparib 2liposomal doxorubicin 2fludarabine phosphate 2fludarabine 2brigimadlin 2Trastuzumab 2Surgical Procedures, Operative 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Azacitidine × Sarcoma × Clear all
NCT04648826 2021-12-17

Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1/2 Withdrawn
DermatologicGenitourinarySarcoma

Carcinoma, Renal Cell, Melanoma, Neoplasms, Germ Cell and Embryonal, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡